Immunoassay Biomarker Test Menu Expansion Market Growth Outlook For 2026: Drivers, Trends And Future Opportunities
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Immunoassay Biomarker Test Menu Expansion Market Forecast: Value Set To Climb From $0.6 Billion To $0.95 Billion
The immunoassay biomarker test menu expansion market size has experienced substantial growth in recent years. It is anticipated to increase from $0.53 billion in 2025 to $0.6 billion in 2026, reflecting a compound annual growth rate (CAGR) of 12.2%. The historical expansion in this market can be linked to factors such as the rising incidence of chronic and infectious diseases, the greater adoption of immunoassay-based diagnostic technologies in clinical laboratories, the expansion of hospital diagnostic infrastructure and laboratory networks, increasing public awareness of early disease detection and preventive healthcare, and augmented government funding for diagnostic research and laboratory modernization.
The market for immunoassay biomarker test menu expansion is anticipated to experience significant expansion over the coming years. This market is projected to grow to $0.95 billion by 2030 at a compound annual growth rate (CAGR) of 12.4%. Factors contributing to this growth during the forecast period include an escalating need for precision medicine and tailored biomarker profiling, greater incorporation of AI and automation into diagnostic laboratories, the widening scope of companion diagnostics within drug development pipelines, increased uptake of multiplex and high-throughput testing platforms, and an enhanced emphasis on early detection programs for cancer and chronic diseases. Key trends anticipated in this period encompass the broadening of multiplex immunoassay panels for detecting multiple disease biomarkers, continuous advancement of high-sensitivity chemiluminescent immunoassay platforms, a surge in the embrace of personalized medicine-guided biomarker testing solutions, the growing incorporation of automated laboratory immunoassay analyzers for high-throughput applications, and an elevated demand for expanding oncology and infectious disease biomarker assays.
Get A Free Sample Report With In-Depth Market Insights:
Immunoassay Biomarker Test Menu Expansion Market Growth Factors: What’s Supporting Expansion?
The anticipated expansion of the immunoassay biomarker test menu market is driven by the growing incidence of chronic and lifestyle diseases. These conditions encompass persistent health issues like heart disease, diabetes, obesity, and hypertension, necessitating continuous medical care. The rise in these diseases can be attributed to an aging populace and lifestyle elements such as inadequate nutrition and lack of exercise, collectively intensifying the burden of chronic health conditions. Expanding the immunoassay biomarker test menu facilitates enhanced disease detection, empowering laboratories to pinpoint a broader spectrum of disease-related biomarkers, thereby enhancing early diagnosis and ongoing monitoring. As an illustration, the US Centers for Disease Control and Prevention, a US-based government public health agency, reported in April 2025 that in 2023, 76.4% of American adults had at least one chronic condition, translating to over 194 million individuals needing consistent health condition oversight and care. Consequently, the escalating occurrence of chronic and lifestyle ailments is stimulating the expansion of the immunoassay biomarker test menu market.
Immunoassay Biomarker Test Menu Expansion Market Segment Landscape: Which Areas Lead Development?
The immunoassay biomarker test menu expansion market covered in this report is segmented –
1) By Type: Enzyme-Linked Immunosorbent Assay Kits, Chemiluminescent Immunoassay Kits, Fluorescent Immunoassay Kits, Multiplex Immunoassay Panels, Rapid Diagnostic Test Kits, Biomarker-Specific Reagents, Calibration Standards, Quality Control Materials
2) By Biomarker Type: Oncology Biomarkers, Cardiac Biomarkers, Endocrine And Hormonal Biomarkers, Infectious Disease Biomarkers, Autoimmune Disease Biomarkers, Neurological Biomarkers, Therapeutic Drug Monitoring Biomarkers
3) By Grade: High-Performance Liquid Chromatography (HPLC) And Ultra-High-Performance Liquid Chromatography (UHPLC) Grade Reagents, Gas Chromatography (GC) Grade Reagents, Analytical Grade Reagents, Liquid Chromatography–Mass Spectrometry (LC-MS) Grade Reagents, Preparative Grade Reagents, Biotechnology Grade Reagents, Technical Grade Filtration Products
4) By Application: Clinical Diagnostics, Companion Diagnostics, Personalized Medicine, Drug Discovery And Clinical Research
5) By End-User: Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Contract Manufacturing Organizations, Academic And Research Institutions, Clinical And Diagnostic Laboratories, Food And Beverage Testing Laboratories, Environmental Testing Laboratories, Government And Regulatory Agencies, Chemical And Industrial Manufacturing Companies
Subsegments:
1) By Enzyme-Linked Immunosorbent Assay Kits: Sandwich Assay Kits, Competitive Assay Kits, Indirect Assay Kits, Direct Assay Kits
2) By Chemiluminescent Immunoassay Kits: Magnetic Particle-Based Kits, Solid Phase Kits, Microplate-Based Kits, Automated Analyzer Kits
3) By Fluorescent Immunoassay Kits: Time-Resolved Fluorescence Kits, Lateral Flow Fluorescence Kits, Microbead-Based Kits, Multiplex Fluorescence Kits
4) By Multiplex Immunoassay Panels: Cytokine Panels, Cardiac Marker Panels, Oncology Panels, Infectious Disease Panels
5) By Rapid Diagnostic Test Kits: Lateral Flow Immunoassays, Colloidal Gold Test Kits, Microfluidic Rapid Kits, Paper-Based Diagnostic Kits
6) By Biomarker-Specific Reagents: Antibodies, Antigens, Conjugates, Detection Reagents
7) By Calibration Standards: Protein Standards, Peptide Standards, Whole Blood Controls, Serum Controls
8) By Quality Control Materials: Positive Controls, Negative Controls, Internal Controls, External Controls
Immunoassay Biomarker Test Menu Expansion Market Industry Trends: What’s Reshaping Demand?
Leading companies operating within the immunoassay biomarker test menu expansion market are concentrating on developing advanced automated immunoassay panels, such as fully integrated immunoassay systems, which streamline sample handling and result reporting in a single automated workflow to minimize operator variability and boost laboratory throughput. Automated immunoassay panels are systems where immunoassay tests are conducted with minimal manual involvement, using robotics or automated analyzers that manage sample preparation, reagent mixing, incubation, detection, and result output, thereby enhancing consistency and accelerating turnaround times in clinical settings. For instance, in May 2024, bioMérieux, a France-based healthcare technology company, launched the VIDA TBI (GFAP, UCH-L1) test for its automated immunoassay platforms VIDAS 3 and VIDAS KUBE. This test features high sensitivity for traumatic brain injury biomarkers, is compatible with on-demand automated workflows 24/7, and offers rapid result turnaround, assisting in efficient clinical triage and reducing unnecessary imaging. The launch reinforces bioMérieux’s immunoassay test menu by expanding its neurological biomarker portfolio and addressing the growing demand for rapid diagnostic solutions in emergency care settings. Moreover, it supports improved clinical decision-making by enabling the timely and accurate detection of brain injury, enhancing patient management, and optimizing healthcare resource utilization.
Immunoassay Biomarker Test Menu Expansion Market Company Landscape And Competitive Strategy
Major companies operating in the immunoassay biomarker test menu expansion market are Tecan Trading AG, Euroimmun Medizinische Labordiagnostika AG, OPKO Health Inc., Autobio Diagnostics Co. Ltd., Promega Corporation, BioLegend Inc., Sekisui Diagnostics LLC, Boditech Med Inc., Dynex Technologies Inc., QuantuMDx Group Ltd., NanoEntek, J. Mitra & Co. Pvt. Ltd., Baebies, ALPCO Diagnostics, Micropoint Bioscience, Coris BioConcept, MiCo BioMed Inc., Kamiya Biomedical Company, Abionic SA, ANP Technologies Inc., Axis-Biosciences / Axela, Epitope Diagnostics Inc., MedMira Inc., Nanomix Inc.
View The Full Immunoassay Biomarker Test Menu Expansion Market Report:
Immunoassay Biomarker Test Menu Expansion Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the immunoassay biomarker test menu expansion market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunoassay biomarker test menu expansion market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
